{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:30:53Z","timestamp":1771471853745,"version":"3.50.1"},"reference-count":43,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Psoriasis (PSO) involves about 1\u20133% of the population, and around 75% of women develop PSO before the age of 40. Official guidelines on the treatment of woman with anti-IL17 and anti-IL23 during this potential childbearing time are not currently available. Objective: To investigate the effectiveness and safety of biologic treatments in women of childbearing age. Methods: At the Dermatology Clinic of the University of Turin, Italy, 172 women aged 20\u201355 years underwent IL-17 and IL-23 inhibitor therapy for moderate-severe PSO and were followed up to 52 weeks in a real-life, retrospective, single-center study. Results: Overall, 40% of patients achieved PASI 100 at week 16, and 72% at week 52. A similar trend was observed for PASI 90 and PASI &lt; 3 with almost 80% and 90% of patients achieving the target at 52 weeks. As for PASI 100, a statistically significant difference (p = 0.004) was found at 16 weeks, with 23.84% of patients achieving PASI 100, with IL-17 and 15.70% with the IL-23 inhibitor. No statistically significant differences were found at 28 and 52 weeks. No statistically significant differences in PASIs at any time points were recorded across the different biologic agents. Forty-six patients discontinued treatment. The most reported side effects were headache, nausea, asthenia, injection site pain, and rhinitis. Conclusions: This study showed that biologic drugs are effective and safe in women of childbearing age, with negligible side effects.<\/jats:p>","DOI":"10.3390\/jcm13216401","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T08:42:13Z","timestamp":1729845733000},"page":"6401","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Psoriasis in Childbearing Age: A Real-Life, Retrospective, Single-Center Study on Anti-IL17 and IL-23 Agents"],"prefix":"10.3390","volume":"13","author":[{"given":"Silvia","family":"Borriello","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-5506","authenticated-orcid":false,"given":"Gabriele","family":"Roccuzzo","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Sciamarrelli","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Macagno","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4529-7068","authenticated-orcid":false,"given":"Francesco","family":"Leo","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-3219","authenticated-orcid":false,"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2016). Global Report on Psoriasis, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.mcna.2009.08.003","article-title":"Evaluation and management of psoriasis: An internist\u2019s guide","volume":"93","author":"Levine","year":"2009","journal-title":"Med. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jaad.2009.05.004","article-title":"Pregnancy outcomes in psoriasis: Why do we know so little?","volume":"61","author":"Horn","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1159\/000509726","article-title":"The influence of pregnancy on the clinical evolution and prognosis of pre-existing inflammatory and autoimmune skin disorders and their management","volume":"237","author":"Nasca","year":"2021","journal-title":"Dermatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/1346-8138.15658","article-title":"Fetal-neonatal and maternal outcomes in women with psoriasis vulgaris: A nationwide population-based registry linkage study in Taiwan","volume":"48","author":"Huang","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/10641950802601179","article-title":"Association of maternal serum CRP, IL-6, TNF-alpha, homocysteine, folic acid and vitamin B12 levels with the severity of preeclampsia and fetal birth weight","volume":"28","author":"Guven","year":"2009","journal-title":"Hypertens Pregnancy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/14712598.2024.2326168","article-title":"Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: Similarities and differences from a clinical multidisciplinary perspective","volume":"24","author":"Roccuzzo","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40264-013-0034-x","article-title":"Ciclosporin use during pregnancy","volume":"36","author":"Paziana","year":"2013","journal-title":"Drug Saf."},{"key":"ref_11","unstructured":"Post, T.W. (2022). Management of psoriasis in pregnancy. UpToDate, UpToDate. Available online: https:\/\/www.uptodate.com\/contents\/management-of-psoriasis-in-pregnancy."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000246811","article-title":"Teratogenic risk with etretinate and acitretin treatment","volume":"189","author":"Geiger","year":"1994","journal-title":"Dermatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijwd.2016.12.003","article-title":"Update on biologic safety for patients with psoriasis during pregnancy","volume":"3","author":"Porter","year":"2017","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_14","first-page":"56","article-title":"A comprehensive survey assessing the family planning needs of women with psoriasis","volume":"98","author":"Lebwohl","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.15665","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017","volume":"177","author":"Smith","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ajg.2008.71","article-title":"Placental transport of immunoglobulins: A clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy","volume":"104","author":"Kane","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 2: Specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Johansen, C.B., Jimenez-Solem, E., Haerskjold, A., Sand, F.L., and Thomsen, S.F. (2018). The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051349"},{"key":"ref_19","first-page":"645","article-title":"S3 Guideline for the treatment of psoriasis vulgaris, update\u2014Short version part 1\u2014Systemic treatment","volume":"16","author":"Nast","year":"2018","journal-title":"J. Der Dtsch. Dermatol. Ges."},{"key":"ref_20","first-page":"1014","article-title":"Tumor necrosis factor-alpha inhibition and VATER association: A causal relationship","volume":"33","author":"Carter","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/ajd.12641","article-title":"Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration","volume":"59","author":"Rademaker","year":"2018","journal-title":"Australas. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ced\/llac098","article-title":"Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: A comparative study on different agents","volume":"48","author":"Roccuzzo","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1111\/jdv.19135","article-title":"Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients","volume":"37","author":"Mastorino","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res."},{"key":"ref_25","unstructured":"European Medicines Agency (2022, February 19). Skyrizi: Summary of Product Characteristics, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/skyrizi-epar-product-information_en.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Bucur, \u0218., Savu, A.P., St\u0103nescu, A.M.A., \u0218erban, E.D., Nicolescu, A.C., Constantin, T., Bobirc\u0103, A., and Constantin, M.M. (2022). Oversight and Management of Women with Psoriasis in Childbearing Age. Medicina, 58.","DOI":"10.3390\/medicina58060780"},{"key":"ref_27","first-page":"821","article-title":"The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: A review of current clinical guidelines. Postepy Dermatol","volume":"37","author":"Owczarek","year":"2020","journal-title":"Alergol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjd.15802","article-title":"Exposure to biological therapies during conception and pregnancy: A systematic review","volume":"178","author":"Pottinger","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7525-7-25","article-title":"The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: A comparison with a selected sample of healthy people. Health Qual","volume":"7","author":"Salaffi","year":"2009","journal-title":"Life Outcomes"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tjog.2018.02.010","article-title":"Diminished ovarian reserve in patients with psoriasis","volume":"57","author":"Alhan","year":"2018","journal-title":"Taiwan J. Obstet. Gynecol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/09513590.2018.1563884","article-title":"Evaluation of ovarian reserve in women with psoriasis","volume":"35","author":"Bilici","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"ref_32","first-page":"305","article-title":"Moderate-to-severe psoriasis and pregnancy: Impact on fertility, pregnancy outcome and treatment perspectives","volume":"154","author":"Caldarola","year":"2019","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_33","unstructured":"European Medicines Agency (2022, February 19). Taltz: Summary of Product Characteristics, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/taltz-epar-product-information_en.pdf."},{"key":"ref_34","unstructured":"European Medicines Agency (2022, February 19). Cosentyx: Summary of Product Characteristics, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf."},{"key":"ref_35","unstructured":"Golbari, N.M., Basehore, B.M., and Zito, P.M. (2021). Brodalumab. StatPearls, StatPearls Publishing."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ajd.12214","article-title":"Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester","volume":"55","author":"Sheeran","year":"2014","journal-title":"Australas. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3315\/jdcr.2012.1116","article-title":"Spontaneous abortion during ustekinumab therapy","volume":"6","author":"Fotiadou","year":"2012","journal-title":"J. Dermatol. Case Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/ecco-jcc\/jjab093","article-title":"Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn\u2019s Disease: Results from the Phase 2 Open-Label Extension Study","volume":"15","author":"Ferrante","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_40","first-page":"34","article-title":"Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment","volume":"22","author":"Mastorino","year":"2024","journal-title":"J. Der Dtsch. Dermatol. Ges."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/jdv.19238","article-title":"Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta-analysis","volume":"37","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/1203475420928376","article-title":"Management of Plaque Psoriasis with Biologic Therapies in Women of Child-Bearing Potential Consensus Paper","volume":"24","author":"Yeung","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamadermatol.2020.5595","article-title":"Pregnancy Outcomes in Women with Moderate-to-Severe Psoriasis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"157","author":"Kimball","year":"2021","journal-title":"JAMA Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6401\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:20:32Z","timestamp":1760113232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":43,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13216401"],"URL":"https:\/\/doi.org\/10.3390\/jcm13216401","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}